exhibit 10. 2 license agreement this license agreement ( this “ agreement ” ) is made and is effective as of june 8, 2004, ( the “ effective date ” ) between synthrx, inc. a delaware corporation ( “ synthrx ” ) and cytrx corporation, a delaware corporation ( “ cytrx ” ) with reference to the following facts : a. cytrx has developed cytrx know - how ( as hereinafter defined ) and has cytrx patent rights ( as hereinafter defined ) in the fields of : ( i ) the composition and use of surface - active copolymers exemplified by poloxamer 188 to treat ischemic or damaged tissue, myocardial damage, stroke, pathological hydrophobic interactions in biological fluids, tissue damaged by reperfusion injury, sickle cell disease, cancer and in performing angioplasty procedures ( with the cytrx know - how and cytrx patent rights in this field referred to collectively as the “ flocor intellectual property ” ) ; ( ii ) the composition and use of surface active copolymers ( exemplified by poloxamers, reverse poloxamers and diether, diester or diamide fatty acid conjugates of poloxyethylene ) to treat infections caused by microorganisms, including bacteria, fungi, and viruses and to treat tumors ( with the cytrx know - how and cytrx patent rights in this field referred to collectively as the “ anti - infectives intellectual property ” ) ; and ( iii ) conventional vaccine adjuvants exemplified by poloxamer p1005 ( with the cytrx know - how and cytrx patent rights in this field referred to collectively as the “ optivax intellectual property ” ). b. cytrx has exclusively licensed to merck & co. ( “ merck ), ivy animal health, inc. ( “ ivy animal health ” ), titermax usa, inc. ( “ titermax ” ) and vical inc. ( “ vical ” ) and has granted an option to acquire an exclusive license to progenies pharmaceuticals, inc. ( “ progenies ” ), cytrx know - how and cytrx patent rights in certain fields under agreements collectively referred to as the cytrx licenses, copies of which are attached hereto as schedule a. c. dr. robert l.